JPH11514866A - 非ｃ群アデノウイルスベクター - Google Patents
非ｃ群アデノウイルスベクターInfo
- Publication number
- JPH11514866A JPH11514866A JP9514303A JP51430397A JPH11514866A JP H11514866 A JPH11514866 A JP H11514866A JP 9514303 A JP9514303 A JP 9514303A JP 51430397 A JP51430397 A JP 51430397A JP H11514866 A JPH11514866 A JP H11514866A
- Authority
- JP
- Japan
- Prior art keywords
- vector
- adenovirus
- nucleic acid
- group
- gene therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 192
- 239000013598 vector Substances 0.000 title claims abstract description 140
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 54
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 53
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 53
- 238000001415 gene therapy Methods 0.000 claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims description 100
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 31
- 230000002950 deficient Effects 0.000 claims description 21
- 230000010076 replication Effects 0.000 claims description 19
- 238000012546 transfer Methods 0.000 claims description 13
- 238000001890 transfection Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000000069 prophylactic effect Effects 0.000 claims description 9
- 230000029812 viral genome replication Effects 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 6
- 230000001988 toxicity Effects 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000003362 replicative effect Effects 0.000 claims description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 description 46
- 108020004414 DNA Proteins 0.000 description 36
- 239000012634 fragment Substances 0.000 description 34
- 239000000047 product Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 18
- 230000006870 function Effects 0.000 description 15
- 239000006166 lysate Substances 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000005215 recombination Methods 0.000 description 13
- 230000006798 recombination Effects 0.000 description 13
- 230000004543 DNA replication Effects 0.000 description 12
- 101150075174 E1B gene Proteins 0.000 description 12
- 108020005202 Viral DNA Proteins 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 8
- 210000000234 capsid Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 201000003883 Cystic fibrosis Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000010370 Adenoviridae Infections Diseases 0.000 description 4
- 206010060931 Adenovirus infection Diseases 0.000 description 4
- 101710164463 Preterminal protein Proteins 0.000 description 4
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 210000002534 adenoid Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- YREOLPGEVLLKMB-UHFFFAOYSA-N 3-methylpyridin-1-ium-2-amine bromide hydrate Chemical group O.[Br-].Cc1ccc[nH+]c1N YREOLPGEVLLKMB-UHFFFAOYSA-N 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001274613 Corvus frugilegus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 101710155188 Hexon-interlacing protein Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000702377 Inovirus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001647769 Mirza Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
- 101710143509 Pre-histone-like nucleoprotein Proteins 0.000 description 1
- 101710111548 Pre-protein VI Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 101710162453 Replication factor A Proteins 0.000 description 1
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 238000007011 Robinson annulation reaction Methods 0.000 description 1
- 101710176276 SSB protein Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000026555 breast adenosis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 125000000086 dCMP group Chemical group 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/537,402 US5837511A (en) | 1995-10-02 | 1995-10-02 | Non-group C adenoviral vectors |
| US08/537,402 | 1995-10-02 | ||
| PCT/US1996/015274 WO1997012986A2 (en) | 1995-10-02 | 1996-09-24 | Non-group c adenoviral vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008179643A Division JP2009028040A (ja) | 1995-10-02 | 2008-07-09 | 非ｃ群アデノウイルスベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11514866A true JPH11514866A (ja) | 1999-12-21 |
| JPH11514866A5 JPH11514866A5 (enExample) | 2004-09-30 |
Family
ID=24142494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9514303A Withdrawn JPH11514866A (ja) | 1995-10-02 | 1996-09-24 | 非ｃ群アデノウイルスベクター |
| JP2008179643A Pending JP2009028040A (ja) | 1995-10-02 | 2008-07-09 | 非ｃ群アデノウイルスベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008179643A Pending JP2009028040A (ja) | 1995-10-02 | 2008-07-09 | 非ｃ群アデノウイルスベクター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5837511A (enExample) |
| EP (1) | EP0866873B1 (enExample) |
| JP (2) | JPH11514866A (enExample) |
| AT (1) | ATE323773T1 (enExample) |
| DE (1) | DE69636055T2 (enExample) |
| WO (1) | WO1997012986A2 (enExample) |
Families Citing this family (161)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| DE69533295T3 (de) * | 1994-02-16 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services | Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma |
| EP1445322B2 (en) * | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US20020068049A1 (en) * | 1998-09-10 | 2002-06-06 | Henderson Daniel R. | Tissue specific adenoviral vectors |
| US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
| US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| US5849561A (en) * | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
| US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| US20040204381A1 (en) * | 1997-11-12 | 2004-10-14 | Moskal Joseph R | Detection and treatment of glyco-enzyme-related disease |
| US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| WO1999055365A1 (en) * | 1998-04-30 | 1999-11-04 | Cornell Research Foundation, Inc. | Adenoviral vectors with tandem fiber proteins |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
| IL141403A0 (en) * | 1998-08-28 | 2002-03-10 | Univ Duke | Deleted adenoviruses and methods of making and administering the same |
| US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| US6224566B1 (en) | 1999-05-04 | 2001-05-01 | Cardiodyne, Inc. | Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium |
| EP1816204B1 (en) * | 1999-05-17 | 2010-10-20 | Crucell Holland B.V. | Recombinant Adenovirus of the Ad26 serotype |
| US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
| WO2002024730A2 (en) * | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
| US7235233B2 (en) * | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
| WO2002068627A2 (en) * | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constucts |
| AU2002332736A1 (en) * | 2001-08-30 | 2003-03-18 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | New adenovirus type 7 vectors |
| US7375206B2 (en) * | 2002-02-22 | 2008-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | Brother of the regulator of imprinted sites (BORIS) |
| ES2335657T3 (es) * | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
| EP1539937A4 (en) * | 2002-08-22 | 2006-07-26 | Merck & Co Inc | METHOD FOR THE REPRODUCTION OF ADENOVIRUS AND PRODUCT VIRUS THEREWITH |
| US20040166091A1 (en) | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
| ES2391975T3 (es) * | 2003-07-25 | 2012-12-03 | Genvec, Inc. | Vacunas a base de vector adenovírico |
| JP2007511507A (ja) * | 2003-11-14 | 2007-05-10 | ジェンベク、インコーポレイティッド | 癌を処置するための治療レジメン |
| BRPI0416920A (pt) * | 2003-11-24 | 2007-01-23 | Canji Inc | redução de cicatriz dérmica |
| ES2329607T3 (es) * | 2004-02-23 | 2009-11-27 | Crucell Holland B.V. | Metodos de purificacion de virus. |
| EP1737885A2 (en) | 2004-04-12 | 2007-01-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of using adenoviral vectors to induce an immune response |
| WO2006008468A2 (en) * | 2004-07-20 | 2006-01-26 | The University Of Warwick | Adenovirus vector and method to manipulate the adenovirus genome |
| WO2006039045A2 (en) * | 2004-09-01 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| WO2006086357A2 (en) * | 2005-02-10 | 2006-08-17 | Merck & Co., Inc. | Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby |
| DK1869171T4 (en) * | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| WO2007027860A2 (en) * | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| US9651543B2 (en) | 2005-08-31 | 2017-05-16 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
| US8450055B2 (en) * | 2005-08-31 | 2013-05-28 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
| BRPI0618441B8 (pt) * | 2005-11-10 | 2021-07-27 | Genvec Inc | vetor adenoviral |
| US20100278870A1 (en) * | 2007-01-09 | 2010-11-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Adenoviral vector-based malaria vaccines |
| US20090202492A1 (en) * | 2008-01-25 | 2009-08-13 | University Of South Florida | Adenovirus vaccine utilizing ikk as adjuvant |
| WO2009149252A1 (en) * | 2008-06-04 | 2009-12-10 | Cornell University | Vaccines for prevention and treatment of addiction |
| CA2742474C (en) | 2008-11-03 | 2016-05-31 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
| US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
| KR101805938B1 (ko) | 2009-10-15 | 2018-01-10 | 얀센 백신스 앤드 프리벤션 비.브이. | 고밀도 세포 배양액에서 아데노바이러스의 정제 방법 |
| AU2010305765B2 (en) | 2009-10-15 | 2015-07-02 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
| WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
| JP5980117B2 (ja) | 2009-11-09 | 2016-08-31 | ジェンヴェック，インコーポレーテッド | サルアデノウイルスベクターの増殖方法 |
| WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
| JP5250155B2 (ja) | 2010-02-15 | 2013-07-31 | クルセル ホランド ベー ヴェー | Ａｄ２６アデノウイルスベクターの製造方法 |
| CN102892429B (zh) | 2010-03-17 | 2016-08-31 | 康奈尔大学 | 基于被破坏的腺病毒的抗滥用药物疫苗 |
| JP2013527753A (ja) | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
| WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
| MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
| WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
| WO2012088041A1 (en) | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
| US9402919B2 (en) | 2011-03-04 | 2016-08-02 | Intrexon Corporation | Vectors conditionally expressing protein |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| CN103987726B (zh) | 2011-10-05 | 2017-10-03 | 金维克有限公司 | 猴(大猩猩)腺病毒或腺病毒载体及其使用方法 |
| JP6757120B2 (ja) | 2011-10-05 | 2020-09-16 | ジェンヴェック エルエルシー | アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法 |
| WO2013052859A2 (en) | 2011-10-05 | 2013-04-11 | Genvec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
| IN2014DN03005A (enExample) | 2011-10-05 | 2015-05-08 | Genvec Inc | |
| WO2013074501A1 (en) | 2011-11-14 | 2013-05-23 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
| EP2809346A1 (en) | 2012-02-02 | 2014-12-10 | GenVec, Inc. | Adenoviral vector-based malaria vaccine |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| CA2864956C (en) | 2012-03-12 | 2021-11-09 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| AP2014007993A0 (en) | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against RSV |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| WO2013154744A1 (en) | 2012-04-13 | 2013-10-17 | Cornell University | Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction |
| US9676824B2 (en) | 2012-05-29 | 2017-06-13 | Genvec, Inc. | Herpes simplex virus vaccine |
| EP2855669B1 (en) | 2012-05-29 | 2018-10-10 | GenVec, Inc. | Modified serotype 28 adenoviral vectors |
| SMT202400297T1 (it) | 2013-03-13 | 2024-09-16 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Proteine f del rsv pre-fusione e loro uso |
| SG11201508567XA (en) | 2013-04-25 | 2015-11-27 | Crucell Holland Bv | Stabilized soluble prefusion rsv f polypeptides |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| MX369156B (es) | 2013-09-19 | 2019-10-30 | Janssen Vaccines & Prevention Bv | Formulaciones de adenovirus mejoradas. |
| US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
| WO2016071306A1 (en) | 2014-11-04 | 2016-05-12 | Crucell Holland B.V. | Therapeutic hpv16 vaccines |
| WO2016103238A1 (en) | 2014-12-24 | 2016-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus f proteins and their use |
| CA2974359A1 (en) | 2015-01-20 | 2016-07-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant parainfluenza virus expressing a chimeric f protein and uses thereof |
| WO2016138160A1 (en) | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| ES2836432T3 (es) | 2015-03-18 | 2021-06-25 | Janssen Vaccines & Prevention Bv | Ensayos para sistemas de expresión recombinante |
| CN107466324B (zh) | 2015-04-14 | 2022-01-14 | 扬森疫苗与预防公司 | 具有双向启动子的表达两种转基因的重组腺病毒 |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| MY195389A (en) | 2015-08-20 | 2023-01-18 | Janssen Vaccines & Prevention Bv | Therapeutic HPV18 Vaccines |
| HK1254838A1 (zh) | 2015-10-06 | 2019-07-26 | Janssen Vaccines & Prevention B.V. | 用於预防生物制品的塑料诱导降解的方法 |
| WO2017139392A1 (en) | 2016-02-08 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant hiv-1 envelope proteins and their use |
| US10808011B2 (en) | 2016-03-09 | 2020-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant HIV-1 envelope proteins and their use |
| CN109069612A (zh) | 2016-04-05 | 2018-12-21 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
| EP3808374A1 (en) | 2016-04-05 | 2021-04-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection |
| US10517944B2 (en) | 2016-05-02 | 2019-12-31 | Janssen Vaccines & Prevention B.V. | Therapeutic HPV vaccine combinations |
| BR112018072865A2 (pt) | 2016-05-12 | 2019-04-30 | Janssen Vaccines & Prevention B.V. | promotor bidirecional potente e equilibrado |
| PE20190110A1 (es) | 2016-05-30 | 2019-01-15 | Janssen Vaccines And Prevention B V | Proteinas f de prefusion del vrs estabilizadas |
| EP3472327B1 (en) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| EP3484506A1 (en) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| US11155832B2 (en) | 2016-09-30 | 2021-10-26 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into T cells |
| WO2018067582A2 (en) | 2016-10-03 | 2018-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 env fusion peptide immunogens and their use |
| WO2018081318A1 (en) | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| CA3043790A1 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
| KR20190104194A (ko) | 2017-01-07 | 2019-09-06 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
| CN110268061B (zh) | 2017-02-09 | 2024-07-16 | 扬森疫苗与预防公司 | 用于表达异源基因的有效的短启动子 |
| US11235056B2 (en) | 2017-03-24 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Glycan-masked engineered outer domains of HIV-1 gp120 and their use |
| BR112019019813A2 (pt) | 2017-03-30 | 2020-04-22 | Univ Queensland | moléculas quiméricas e usos das mesmas |
| CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| EP4400174A3 (en) | 2017-09-01 | 2024-10-23 | The Francis Crick Institute Limited | Immunoregulatory molecules and uses therefor |
| BR112020004143A2 (pt) | 2017-09-15 | 2020-09-01 | Janssen Vaccines & Prevention B.V. | método para a indução segura de imunidade contra vírus sincicial respiratório (rsv) |
| WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
| US11136356B2 (en) | 2017-10-16 | 2021-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| MX2020004487A (es) | 2017-10-31 | 2020-08-13 | Janssen Vaccines & Prevention Bv | Adenovirus y usos de estos. |
| EP3704256A1 (en) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| AU2018359492B2 (en) | 2017-10-31 | 2023-12-14 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| US11236361B2 (en) | 2017-10-31 | 2022-02-01 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| US11447526B2 (en) | 2018-01-23 | 2022-09-20 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| CA3092372A1 (en) | 2018-02-26 | 2019-08-29 | AnTolRx, Inc. | Tolerogenic liposomes and methods of use thereof |
| AU2019231654B2 (en) | 2018-03-06 | 2025-12-11 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| AU2019231652B2 (en) | 2018-03-06 | 2025-05-22 | Precigen, Inc. | Hepatitis B vaccines and uses of the same |
| US12162910B2 (en) | 2018-10-22 | 2024-12-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant gp120 protein with V1-loop deletion |
| PH12021550974A1 (en) | 2018-11-13 | 2022-05-02 | Janssen Vaccines & Prevention Bv | Stablized pre-fusion rsv f proteins |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3959228A1 (en) | 2019-04-25 | 2022-03-02 | Janssen Vaccines & Prevention B.V. | Recombinant influenza antigens |
| WO2020223205A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
| AU2020275910A1 (en) | 2019-05-15 | 2021-11-04 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
| JP2022532723A (ja) | 2019-05-15 | 2022-07-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与 |
| US20200390718A1 (en) | 2019-05-28 | 2020-12-17 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| EP4025247A1 (en) | 2019-09-05 | 2022-07-13 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| EP4038088A1 (en) | 2019-10-03 | 2022-08-10 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| US20220403438A1 (en) | 2019-10-08 | 2022-12-22 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| EP4073102A4 (en) | 2019-12-12 | 2024-05-08 | Ting Therapeutics LLC | Compositions and methods for the prevention and treatment of hearing loss |
| WO2021163365A1 (en) | 2020-02-11 | 2021-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 vaccine |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
| US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
| US11773391B2 (en) | 2020-04-01 | 2023-10-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19 |
| WO2021209897A1 (en) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| WO2021222639A2 (en) | 2020-04-29 | 2021-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant human metapneumovirus f proteins and their use |
| US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
| EP4175721A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022035860A2 (en) | 2020-08-10 | 2022-02-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Replication-competent adenovirus type 4-hiv env vaccines and their use |
| US20240228549A1 (en) | 2021-04-29 | 2024-07-11 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Prefusion-stabilized lassa virus glycoprotein complex and its use |
| EP4380613A1 (en) | 2021-08-03 | 2024-06-12 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| WO2023091696A1 (en) | 2021-11-19 | 2023-05-25 | Christiana Care Gene Editing Institute, Inc. | Adenovirus delivery system for cancer treatment |
| WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| US20250197455A1 (en) | 2022-03-27 | 2025-06-19 | TThe United States of America, as represented by the Secretary, Department of Health and Human Servi | Base-covered hiv-1 envelope ectodomains and their use |
| WO2023196898A1 (en) | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
| EP4338727A1 (en) | 2022-09-14 | 2024-03-20 | Roquette Freres | Adenovirus formulations |
| WO2024233783A1 (en) | 2023-05-09 | 2024-11-14 | Cornell University | Expression cassette coding for vascular endothelial growth factor |
| WO2024249626A1 (en) | 2023-05-30 | 2024-12-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 envelope triple tandem trimers and their use |
| WO2025158316A1 (en) | 2024-01-26 | 2025-07-31 | Janssen Biotech, Inc. | Ovarian neoantigens and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA858044B (en) * | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| EP0638316B1 (en) * | 1993-08-11 | 2003-05-28 | Wyeth | Recombinant adenovirus vaccines |
| US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
| WO1996009399A2 (en) * | 1994-09-23 | 1996-03-28 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
-
1995
- 1995-10-02 US US08/537,402 patent/US5837511A/en not_active Expired - Lifetime
-
1996
- 1996-09-24 DE DE69636055T patent/DE69636055T2/de not_active Revoked
- 1996-09-24 AT AT96935925T patent/ATE323773T1/de not_active IP Right Cessation
- 1996-09-24 EP EP96935925A patent/EP0866873B1/en not_active Revoked
- 1996-09-24 JP JP9514303A patent/JPH11514866A/ja not_active Withdrawn
- 1996-09-24 WO PCT/US1996/015274 patent/WO1997012986A2/en not_active Ceased
-
2008
- 2008-07-09 JP JP2008179643A patent/JP2009028040A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997012986A2 (en) | 1997-04-10 |
| ATE323773T1 (de) | 2006-05-15 |
| DE69636055D1 (de) | 2006-05-24 |
| WO1997012986A3 (en) | 1997-06-19 |
| DE69636055T2 (de) | 2007-04-12 |
| JP2009028040A (ja) | 2009-02-12 |
| US5837511A (en) | 1998-11-17 |
| EP0866873B1 (en) | 2006-04-19 |
| EP0866873A2 (en) | 1998-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH11514866A (ja) | 非ｃ群アデノウイルスベクター | |
| JP3816518B2 (ja) | 相補的なアデノウイルスベクター系と細胞系 | |
| JP3299761B2 (ja) | 相補的なアデノウィルスベクター系と細胞株 | |
| EP0988389B1 (en) | Method for the production of non-group c adenoviral vectors | |
| WO1997012986A9 (en) | Non-group c adenoviral vectors | |
| AU730278B2 (en) | Complementary adenoviral vector systems and cell lines | |
| AU703768C (en) | Complementary adenoviral vector systems and cell lines | |
| MXPA98004716A (en) | Complementary systems of adenoviral vectors and cell lines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061010 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070110 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070710 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070911 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071022 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071018 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080904 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081023 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090115 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100215 |